1 / 28

Trans-catheter Aortic Valve Replacement: a UK update.

Trans-catheter Aortic Valve Replacement: a UK update. Dr Martyn Thomas Guys and St Thomas’ Hospital. So, is there a clinical need for less invasive method of replacing the aortic valve??. Severe Symptomatic Aortic Stenosis is a fatal condition.

mayten
Télécharger la présentation

Trans-catheter Aortic Valve Replacement: a UK update.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Trans-catheter Aortic Valve Replacement: a UK update. Dr Martyn Thomas Guys and St Thomas’ Hospital

  2. So, is there a clinical need for less invasive method of replacing the aortic valve??

  3. Severe Symptomatic AorticStenosis is a fatal condition. “Surgical intervention should be performed promptly once even… minor symptoms occur”1 Valvular Aortic Stenosis in Adults(Average Course) Chart: Ross J Jr, Braunwald E. Aortic stenosis. Circulation 1968;38 (Suppl 1) 1 C.M. Otto. Valve Disease: Timing of Aortic Valve Surgery. Heart 2000 Chart:: Ross J Jr, Braunwald E. Aortic stenosis. Circulation. 1968;38 (Suppl 1):61-7.

  4. 31.8% did not undergo intervention, most frequently because of comorbidities

  5. Treated vs. Untreated

  6. Prof. Alain CribierFirst Clinical Experiences First described percutaneous aortic valve interventions in 1985 Proved that a stent could be deployed without removing the diseased native valve Implanted first percutaneous aortic valve on a patient on April 16, 2002

  7. Currently available systems in the UK. • Corevalve: trans-femoral • Registry complete. CE mark. Now in commercial phase. • Edwards Sapien Valve: trans-femoral and transapical. • European Registry complete at the end of Jan. CE mark for both approaches. Now in commercial phase.

  8. Self-Expanding Multi-level Support Frame • Diamond cell configuration • Nitinol (memory shaped) • Multi-level design incorporates three different areas of radial and hoop strength • Low radial force areaorients the system • Constrained area toavoid coronariesand featuringsupra-annularvalveleaflets • High radial forcefor secure anchoring – no recoil – constant force mitigates leak • Radiopaque

  9. Porcine Pericardial Tissue Valve • Specifically designed for transcatheter delivery • Single layer porcine pericardium • Tri-leaflet configuration • Tissue valve sutured to frame • Standard tissue fixation techniques • 200M cycle AWT testing completed • Supra-annular valvefunction • Intra-annular implantationand sealing skirt

  10. 18F Delivery Catheter System Over-the-wire 0.035 compatible 12F shaft body 18F distal end Dual speed releasehandle

  11. Technology Progress & Total Experience Generation 1 25F Transcatheter 14 patients Generation 2 21F Transcatheter 2004-2005 Generation 3 18F Percutaneous 65 patients* 2005-2006 184 patients** * Including 2 ReDo ** Updated August 30, 2007 Including Expanded Evaluation Registry Oct 2006

  12. CoreValve PAVR ReValving™ System Updated August 31, 2007

  13. Procedural Results – N=175 Procedural Success161 (92%) Mean Total Procedure Time 170 ± 77 Minutes Mean ReValving™ Time 11 ± 14 Minutes Discharged with CoreValve 159 (91%) Discharged after surgical conversion 3 (2%)

  14. Edwards SAPIEN™ THV Access to the aortic valve Transapical Approach Transfemoral Approach

  15. Cribier-Edwards™ and Edwards SAPIEN™ THV* Aortic Transfemoral/Transapical Trial Implants (21 Dec 07 Update) * The Edwards SAPIEN™ valve incorporates bovine pericardial tissue and TFX™ treatment

  16. RetroFlex RetroFlex II RetroFlex II Offers: • Greatly improved native valve crossability • Smoother tracking • Improved handle functionality • Fewer system components

  17. Transfemoral Procedure: Edwards

  18. Transfemoral Procedure: Edwards

  19. Valve deployment with 3D echo.

  20. The UK position • 15 centres would like to start a programme. • Active centres, n=6. • Number of cases: • - Corevalve 71 • - Edwards 16 • Early Mortality approx 7%. 3/87 cath lab deaths, 5/87 in patient deaths (2 non cardiac) and 6/87 deaths at 3/12. • Also pacemaker, surgical conversion, peripheral vascular complications, stroke, pericardial drain. • Complex procedure but considering the patient mix encouraging.

  21. Training • Centre selection currently controlled by industry. • Responsible attitude being taken. • MHRA (or whatever they are now called!) happy and do not feel central control is necessary. • Training consists (in general) of theory, simulators, observation and cases performed with proctors. • 2008 an interesting, dangerous and challenging year!!

  22. UK Funding • Currently undergoing a NICE assessment. • Most centres trying to use a “surgical” tariff. • “Top ups” being locally negotiated with PCTs. • Early “NICE” assessment (like PFO closure) may facilitate the process.

  23. Trans-catheter Aortic Valve Replacement: a UK update.Conclusions • 2008 will be an exciting but “dangerous” year for trans-catheter heart valve replacement. • Training and case selection is all. • Irresponsible use of the device could set Europe and the UK back for many years. • This exciting development in interventional cardiology could well be the future for tertiary/surgical centre intervention (at least in the medium term!)

More Related